Tuberculosis Treatment Market: By Class of Drugs (First Line Drugs, Second Line Drugs), By TB (TB, Multi Drug Resistance TB), By Route Of Administration (Oral, Parental), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography    

Purchase Option

$ 4400
$ 6600
$ 8900

Tuberculosis Treatment Market size was valued at USD 1.7 billion in 2022 and is expected to grow at a CAGR of 6.1% from 2023 to 2029. Tuberculosis is an infectious disease usually caused by the bacteria Mycobacterium tuberculosis. TB usually affects the lungs and transmits to direct contact with the sputum of the infected person. The global tuberculosis treatment market is projected to grow at significant rates owing to an increase in the prevalence of immunosuppressant diseases such as HIV around the globe. HIV-infected patients are very susceptible to being infected by TB. According to UNAIDS statistics, about 36.7 million people were living with HIV in 2016. Companies operating in the global market focus on new product developments and launches to maximize their share in the market. Furthermore, collaborations and acquisitions are also key strategies adopted by the companies to strengthen their position in the global market. For instance, in August 2017, Johnson & Johnson Services Inc. entered into a partnership with the Institute of Microbial Technology to accelerate the discovery of novel treatments for tuberculosis.

The rising number of medicine recalls is a key stumbling block to the market's expansion. Manufacturers of tuberculosis drugs face obstacles such as an increase in product recalls due to packaging or manufacturing defects. In India, for example, Sandoz recalled a batch of tuberculosis (TB) medications due to improper packaging. Furthermore, the Philippines Food and Medicine Administration recalled Novartis' drug Onecure in 2016 due to an insufficient amount of rifampicin in the drug. Another element limiting the market's growth is the high cost of medications. Second-line therapy medications are more expensive than first-line treatment drugs, and they have more side effects and high levels of toxicity. Although advanced technologies and the development of novel therapies are expected to reduce the time it takes to treat tuberculosis, most cases can take up to 6 months to treat with currently available drugs. Despite existing medicines and ongoing TB treatment drug advances, there is a constant need to increase patients' access to appropriate TB medicines, particularly in the areas of MDR TB and pediatric TB.

Tuberculosis Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

6.1%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Tuberculosis Treatment Market Dynamics

Increase in the prevalence of the disease especially in developing countries is the major driving factor for the growth of tuberculosis treatment market globally. According to World health organization, there were 10.4 million tuberculosis cases were reported in 2016. In addition, growth in prevalence of multidrug-resistant tuberculosis and rise in awareness related to TB due to the initiatives by the various organization expected to boost the market growth over the forecast period. However, lack of reimbursement coverage in low and middle-income countries and high cost of development of drugs are expected to hamper the market growth over the forecast period.

Tuberculosis Treatment Market Segmentation

By Class of Drugs
  • First Line Drugs
  • Second Line Drugs
By TB
  • TB
  • Multi-Drug Resistance TB
By Route of Administration
  • Oral
  • Parental
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Frequently Asked Questions

The tuberculosis treatment market size was valued at USD 1.7 billion in 2022

The tuberculosis treatment market key players are Bayer AG (Germany) AstraZeneca PLC (U.S.) GlaxoSmithKline PLC (U.S.) Eli Lilly And Company (U.S.) Novartis AG (Switzerland ) Lupin Pharmaceuticals Inc. (India) Sandoz International GmbH (Germany)

The tuberculosis treatment market segments are by class of drugs, tb, route of administration and by distribution channel

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
1.Executive Summary
2.Global Tuberculosis Treatment Market Introduction 
2.1.Global Tuberculosis Treatment Market  - Taxonomy
2.2.Global Tuberculosis Treatment Market  - Definitions
2.2.1. By Class of Drugs
2.2.2. By TB
2.2.3. By Route of Administration
2.2.4. By Distribution Channel
2.2.5. By Region
3.Global Tuberculosis Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Tuberculosis Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Tuberculosis Treatment Market  By Class of Drugs, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. First Line Drugs
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Second Line Drugs
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Tuberculosis Treatment Market  By TB, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. TB
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Multi-Drug Resistance TB
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7.Global Tuberculosis Treatment Market  By Route of Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Oral
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Parental
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Tuberculosis Treatment Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Others
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9.Global Tuberculosis Treatment Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Tuberculosis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Class of Drugs Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.First Line Drugs
10.1.2.Second Line Drugs
10.2.  TB Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.TB
10.2.2.Multi-Drug Resistance TB
10.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Oral
10.3.2.Parental
10.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacies
10.4.2.Retail Pharmacies
10.4.3.Others
10.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Tuberculosis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Class of Drugs Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.First Line Drugs
11.1.2.Second Line Drugs
11.2.  TB Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.TB
11.2.2.Multi-Drug Resistance TB
11.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Oral
11.3.2.Parental
11.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacies
11.4.2.Retail Pharmacies
11.4.3.Others
11.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
12.Asia Pacific (APAC) Tuberculosis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Class of Drugs Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.First Line Drugs
12.1.2.Second Line Drugs
12.2.  TB Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.TB
12.2.2.Multi-Drug Resistance TB
12.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Oral
12.3.2.Parental
12.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacies
12.4.2.Retail Pharmacies
12.4.3.Others
12.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Tuberculosis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Class of Drugs Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.First Line Drugs
13.1.2.Second Line Drugs
13.2.  TB Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.TB
13.2.2.Multi-Drug Resistance TB
13.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Oral
13.3.2.Parental
13.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacies
13.4.2.Retail Pharmacies
13.4.3.Others
13.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Tuberculosis Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
14.1. Class of Drugs Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.First Line Drugs
14.1.2.Second Line Drugs
14.2.  TB Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.TB
14.2.2.Multi-Drug Resistance TB
14.3.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Oral
14.3.2.Parental
14.4.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacies
14.4.2.Retail Pharmacies
14.4.3.Others
14.5.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Bayer AG (Germany)
15.2.2.AstraZeneca PLC (U.S.)
15.2.3.GlaxoSmithKline PLC (U.S.)
15.2.4.Eli Lilly And Company (U.S.)
15.2.5.Novartis AG (Switzerland )
15.2.6.Lupin Pharmaceuticals Inc. (India)
15.2.7.Pfizer Inc. (U.S.)
15.2.8.Johnson & Johnson Services Inc. (U.S.)
15.2.9.Sanofi S.A. (France)
16. Research Methodology 
17. Appendix and Abbreviations 
  • Bayer AG (Germany)
  • AstraZeneca PLC (U.S.)
  • GlaxoSmithKline PLC (U.S.)
  • Eli Lilly And Company (U.S.)
  • Novartis AG (Switzerland )
  • Lupin Pharmaceuticals Inc. (India)
  • Sandoz International GmbH (Germany)
  • Pfizer Inc. (U.S.)
  • Johnson & Johnson Services Inc. (U.S.)
  • Sanofi S.A. (France)

Adjacent Markets